Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Authors’ Reply
BRIDGING THE GAP
BRIEF COMMUNICATION
BRIEF REPORT
Case Report
Case Reports
Case Series
CME
CME ARTICLE
CME articles - Practice points
COMMENTARY
CONFERENCE REPORT
CONTROVERSY
Correspondence
Correspondences
CUTANEOUS PATHOLOGY
DRUG REVIEW
E-CHAT
Editorial
EDITORIAL COMMENTARY
ERRATUM
ETHICAL HOTLINE
ETHICS
Field: Evolution of dermatologic surgergy
FOCUS
FROM THE ARCHIVES OF INDIAN JOURNAL OF DERMATO SURGERY
From the Editor's Desk
FROM THE LITERATURE
GUEST EDITORIAL
Guidelines
Images in Clinical Practice
Images in Dermatosurgery
INNOVATION
Innovations
INVITED COMMENTARY
JCAS Symposium
LETTER
Letter to Editor
Letter to the Editor
LETTERS
Message from the President
NEW HORIZON
Original Article
Practice Point
Practice Points
PRESIDENTIAL SPEECH
QUIZ
RESEARCH ARTICLE
Resident’s Page
Review
Review Article
Review Articles
SHORT COMMUNICATION
Spot the Diagnosis [Quiz]
STUDY
SURGICAL PEARL
SYMPOSIUM
Symposium—Lasers
Symposium: Hair in Dermatology
Symposium: Lasers Review Article
View Point
VIEWPOINT
VIEWPOINTS
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Authors’ Reply
BRIDGING THE GAP
BRIEF COMMUNICATION
BRIEF REPORT
Case Report
Case Reports
Case Series
CME
CME ARTICLE
CME articles - Practice points
COMMENTARY
CONFERENCE REPORT
CONTROVERSY
Correspondence
Correspondences
CUTANEOUS PATHOLOGY
DRUG REVIEW
E-CHAT
Editorial
EDITORIAL COMMENTARY
ERRATUM
ETHICAL HOTLINE
ETHICS
Field: Evolution of dermatologic surgergy
FOCUS
FROM THE ARCHIVES OF INDIAN JOURNAL OF DERMATO SURGERY
From the Editor's Desk
FROM THE LITERATURE
GUEST EDITORIAL
Guidelines
Images in Clinical Practice
Images in Dermatosurgery
INNOVATION
Innovations
INVITED COMMENTARY
JCAS Symposium
LETTER
Letter to Editor
Letter to the Editor
LETTERS
Message from the President
NEW HORIZON
Original Article
Practice Point
Practice Points
PRESIDENTIAL SPEECH
QUIZ
RESEARCH ARTICLE
Resident’s Page
Review
Review Article
Review Articles
SHORT COMMUNICATION
Spot the Diagnosis [Quiz]
STUDY
SURGICAL PEARL
SYMPOSIUM
Symposium—Lasers
Symposium: Hair in Dermatology
Symposium: Lasers Review Article
View Point
VIEWPOINT
VIEWPOINTS
View/Download PDF

Translate this page into:

Correspondence
15 (
4
); 436-438
doi:
10.4103/JCAS.JCAS_84_21

Nonmelanoma Skin Cancer in COVID-19 Era: The Foggia Experience

Unit of Reconstructive and Plastic Surgery, Ospedali Riuniti di Foggia, University of Foggia, Foggia, Italy

Address for correspondence: Dr. Fedele Lembo, Unit of Reconstructive and Plastic Surgery, Ospedali Riuniti di Foggia, Foggia 71122, Italy. E-mail: lembofedele@gmail.com

Licence

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Disclaimer:
This article was originally published by Wolters Kluwer - Medknow and was migrated to Scientific Scholar after the change of Publisher.

Dear Editor,

Italy is one of the most affected countries by coronavirus disease-2019 (COVID-19) in 2020.[1] After March 9, social restrictions were applied and public hospitals were completely rationalized. New safe pathways for COVID patients have been created, any screening visits have been blocked, management of oncologic patients has been guaranteed, and telemedicine has been implemented for consultation.[2345]

During the COVID-19 pandemic, our Plastic Surgery Department worked to keep cancer services active despite significant operative problems, including reduction and reallocation of anesthesiologists, and reduction of the medical and nurse workforce due to contagion.

We investigated the differences in patients who presented to our department for nonmelanoma skin cancer (NMSC) excision in 2020 (COVID-19 era) as compared with those who presented at the same time in 2019.

We performed a retrospective, single-center case-control study comparing 531 patients treated for NMSC during the COVID-19 era in 2020 to results from 817 patients treated in the previous year. Data collected were compared using chi-squared tests for dichotomous data and unpaired t tests for contiguous data, with a P < 0.05.

The results are summarized in Table 1. Sex, age, body mass index (BMI), ASA score, smoking, diabetes, and lesion location were compared, and not significant difference was noted. In 2020 group, we identified a significant increase of squamous cell carcinomas (SCC) excised as compared with the previous year (29.2% vs. 21.9%, P < 0.05). Skin cancers excised in 2020 were significantly larger (38.7 ± 5.2 mm vs. 27.2 ± 7.1 mm, P < 0.05) and these lesions required more complex reconstruction (i.e., skin flap or graft), with fewer lesions amenable to direct closure (47.5% vs. 58.3%, P < 0.05). We observed a significant reduction of reconstruction with dermal substitutes in COVID-19 era (2.4% vs. 6.9%, P < 0.05), probably for the necessity of single-stage treatment. No statistical difference was observed between the two groups in incomplete excision rate that was lower in 2020 than in 2019 (3.2% vs. 9.3%, P = 0.31). The use of absorbable sutures in COVID-19 era was significantly increased (87.3% vs. 38.4%, P < 0.05).

Table 1 Summary of results
2019 (no. of lesions =  817) 2020 (no. of lesions = 531 ) P
Age (mean [SD]) 73.5 (7.2) 74.2 (6.9) 0.45
Sex (n) 0.23
 Males 506 321
 Females 311 210
BMI (SD) 25.3 (4.21) 26.2 (5.41) 0.14
ASA score
I 458 (56%) 354 (66.7%) 0.32
II 312 (38.2%) 171 (32.2%)
III 47 (5.8%) 6 (1.1%)
IV 0 0
Smoke
Yes 523 (64%) 288 (54.2%) 0.12
No 294 (36%) 243 (45.8%)
Diabetes mellitus
Yes 172 (21%) 105 (19.8%) 0.22
No 645 (79%) 426 (80.2%)
Mean time to procedure (days) 37 32 0.11
Body site (%) 0.27
 Head––neck 63.2 68.6
 Trunk 22.8 18.5
 Upper limb 11.7 10.4
 Lower limb 2.3 1.5
Histological diagnosis (n)(%) 0.021
 BCC (basal cell carcinoma) 610 (74.7%) 362 (68.2%)
 SCC (squamous cell carcinoma) 179 (21.9%) 155 (29.2%)
 Actinic keratosis 17 (2.1%) 10 (1.9%)
 Bowen's disease 6 (0.7%) 3 (0.6%)
 Others 5 (0.6%) 1 (0.1%)
Largest tumor diameter in mm (mean [SD]) 27.2 (7.1) 38.7 (5.2) 0.014
Reconstruction (%) 0.031
 Direct closure 58.3 47.5
 Skin graft 27.8 32.2
 Dermal substitute 6.9 2.4
 Local flap 7 17.9
Incomplete––all lesions (%) 9.3 3.2 0.45
Type of suture 0.015
 Absorbable 38.4% 87.3%
 Not absorbable 61.6% 12.7%

The results of our study showed that in the COVID-19 era our department treated a minor number of NMSCs (531 vs. 817), but significantly larger, with a higher proportion of SCCs requiring more complex reconstruction after excision. We observed a significant reduction of patients admitted to our hospitals, probably patients feared becoming infected with SARS-CoV-2 in hospital stay. On the contrary, the reasons for increased size of NMSC treated in 2020 are likely to be multifactorial: the cancer screening opportunities are significantly interrupted (missed or later diagnosis); the patients have had delayed presentation to healthcare services; and the face-to-face appointments in primary care are reduced.

However, in our study, we found no difference in the time from initial diagnosis to definitive treatment between groups. In fact, although under operative problems, such as staff redeployed and operating rooms closed, our service continued to treat cancers in a timely manner.

In this current global lockdown scenario, our aim is to guarantee high-quality and timely care, minimizing COVID-19 infection risk.

We modified our treatment protocol following the Plastic Surgery and Dermatological Societies guidelines regarding the measures to minimize the transmission risk of COVID-19, covering topics including hand washing, personal protective equipment (PPE) for patients and providers, risk of aerosolizing, ventilation, and disinfecting rooms between patient encounters. With our measures, there has been no known transmission of COVID-19 associated with surgery.

Moreover, our approach is based on reducing the operative times and the hospital stay, minimizing the necessity of general anesthesia, preferring simple reconstructive procedure according to the principle of “one-shot” surgery, and preferring dissolvable sutures to prevent need for additional visit.

We expect NMSC diagnosis to increase significantly in the coming months, although it is unpredictable if this pandemic-related delay could affect size, thickness, and patient prognosis. It should be considered to emphasize the fact that although aggressive and contagious, COVID-19 is not the only cause of death and that cancer must be diagnosed and promptly treated in specialized center.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

  1. . Coronavirus disease 2019 (COVID-19). Situation report. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/2020
  2. , , , . A summary of recommendations for plastic surgeons during the coronavirus disease 2019 outbreak. Plast Reconstr Surg Glob Open. 2020;8:e3039.
    [Google Scholar]
  3. , , , , , . Coronavirus disease 2019 state guidelines on elective surgery: Considerations for plastic and reconstructive surgeons. Plast Reconstr Surg Glob Open. 2020;8:e2904.
    [Google Scholar]
  4. , , , , , . Characterising non-melanoma skin cancer undergoing surgical management during the COVID-19 pandemic. J Plast Reconstr Aesthet Surg. 2020;S1748-6815:30539-8.
    [Google Scholar]
  5. , , , , . Management of patients with melanoma and non-melanoma skin cancers in the coronavirus disease 2019 era. Chin Med J (Engl). 2020;133:2017-9.
    [Google Scholar]
Show Sections